FDA Expands Diagnostic Test Use for Several Cancers

The U.S. Food and Drug Administration (FDA) has approved broader application of Agilent's PD-L1 IHC 22C3 pharmDx diagnostic. This expansion allows for identifying more cancer patients, including those with esophageal squamous cell carcinoma and triple-negative breast cancer, who may benefit from specific treatments. This regulatory action aims to improve treatment eligibility determination for various cancer types.